IRLAB Therapeutics (IRLAB A.ST) Stock Price

IRLAB Therapeutics Price

OMX·CLOSED
1.72SEK+0.0020 (+0.12 %)
Market closed

Over the last 8 years IRLAB Therapeutics grew revenue by 125.0% annually, reaching 94.63 M SEK. For IRLAB Therapeutics, the net margin of -87.8% is up versus -369,692.3% a few years ago. The stock trades about 43% above its 52-week low.

IRLAB Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of IRLAB Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IRLAB Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IRLAB Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

IRLAB Therapeutics Stock Price History
DateIRLAB Therapeutics Price
8/21/20261.72 SEK
8/20/20261.72 SEK
8/19/20261.77 SEK
8/17/20261.68 SEK
8/14/20261.65 SEK
8/13/20261.62 SEK
8/12/20261.60 SEK
8/11/20261.53 SEK
8/10/20261.51 SEK
8/7/20261.52 SEK
8/6/20261.34 SEK
8/5/20261.36 SEK
8/4/20261.32 SEK
7/31/20261.32 SEK
7/30/20261.30 SEK
7/29/20261.32 SEK
7/28/20261.28 SEK
7/27/20261.25 SEK
7/24/20261.27 SEK
7/23/20261.30 SEK
7/22/20261.33 SEK
7/21/20261.35 SEK
7/20/20261.26 SEK
7/17/20261.31 SEK
7/15/20261.33 SEK
7/14/20261.39 SEK
7/13/20261.39 SEK
7/10/20261.40 SEK
7/9/20261.38 SEK
7/8/20261.33 SEK
7/7/20261.32 SEK
7/6/20261.31 SEK
7/3/20261.28 SEK
7/2/20261.31 SEK
7/1/20261.24 SEK
6/30/20261.24 SEK
6/29/20261.20 SEK
6/26/20261.22 SEK
6/25/20261.22 SEK
6/24/20261.22 SEK
6/23/20261.22 SEK
6/22/20261.21 SEK
6/18/20261.24 SEK
6/17/20261.23 SEK
6/16/20261.20 SEK
6/15/20261.20 SEK
6/12/20261.24 SEK
6/11/20261.27 SEK
6/10/20261.21 SEK
6/9/20261.24 SEK
6/8/20261.24 SEK
6/5/20261.24 SEK
6/4/20261.24 SEK
6/3/20261.26 SEK
6/2/20261.20 SEK
6/1/20261.24 SEK
5/29/20261.22 SEK
5/28/20261.30 SEK
5/27/20261.29 SEK
5/26/20261.28 SEK
5/25/20261.26 SEK
5/22/20261.26 SEK
5/21/20261.26 SEK
5/20/20261.29 SEK
5/19/20261.25 SEK
5/18/20261.27 SEK
5/15/20261.25 SEK
5/13/20261.22 SEK
5/12/20261.24 SEK
5/11/20261.26 SEK
5/8/20261.26 SEK
5/7/20261.26 SEK
5/6/20261.27 SEK
5/5/20261.20 SEK
5/4/20261.41 SEK
4/30/20261.41 SEK
4/29/20261.42 SEK
4/28/20261.49 SEK
4/27/20261.54 SEK
4/24/20261.45 SEK
4/23/20261.47 SEK
4/22/20261.48 SEK
4/21/20261.52 SEK
4/20/20261.55 SEK
4/17/20261.55 SEK
4/16/20261.52 SEK
4/15/20261.54 SEK
4/14/20261.57 SEK
4/13/20261.52 SEK
4/10/20261.56 SEK
4/9/20261.49 SEK
4/8/20261.58 SEK
4/7/20261.52 SEK
4/2/20261.43 SEK
4/1/20261.43 SEK
3/31/20261.50 SEK
3/30/20261.51 SEK
3/27/20261.51 SEK
3/26/20261.53 SEK
3/25/20261.55 SEK
3/24/20261.52 SEK
3/23/20261.48 SEK
3/20/20261.58 SEK
3/19/20261.59 SEK
3/18/20261.60 SEK
3/17/20261.59 SEK
3/16/20261.55 SEK
3/13/20261.59 SEK
3/12/20261.58 SEK
3/11/20261.59 SEK
3/10/20261.64 SEK
3/9/20261.59 SEK
3/6/20261.60 SEK
3/5/20261.62 SEK
3/4/20261.67 SEK
3/3/20261.63 SEK
3/2/20261.55 SEK
2/27/20261.72 SEK
2/26/20261.72 SEK
2/25/20261.59 SEK
2/24/20261.58 SEK
2/23/20261.70 SEK
2/20/20261.80 SEK
2/19/20261.85 SEK
2/18/20261.71 SEK
2/17/20261.78 SEK
2/16/20261.74 SEK
2/13/20261.84 SEK
2/12/20261.86 SEK
2/11/20261.80 SEK
2/10/20261.69 SEK
2/9/20261.63 SEK
2/6/20261.68 SEK
2/5/20261.68 SEK
2/4/20261.70 SEK
2/3/20261.70 SEK
2/2/20261.80 SEK
1/30/20261.81 SEK
1/29/20261.79 SEK
1/28/20261.79 SEK
1/27/20261.76 SEK
1/26/20261.81 SEK
1/23/20261.88 SEK
1/22/20261.90 SEK
1/21/20261.90 SEK
1/20/20261.90 SEK
1/19/20261.90 SEK
1/16/20262.00 SEK
1/15/20262.00 SEK
1/14/20261.98 SEK
1/13/20262.06 SEK
1/12/20262.00 SEK
1/9/20262.00 SEK
1/8/20261.98 SEK
1/7/20262.00 SEK
1/5/20262.03 SEK
1/2/20262.01 SEK
12/30/20251.97 SEK
12/29/20251.92 SEK
12/23/20251.97 SEK
12/22/20251.88 SEK
12/19/20251.92 SEK
12/18/20251.94 SEK
12/17/20251.95 SEK
12/16/20251.93 SEK
12/15/20251.90 SEK
12/12/20251.94 SEK
12/11/20251.97 SEK
12/10/20251.98 SEK
12/9/20252.02 SEK
12/8/20252.17 SEK
12/5/20252.32 SEK
12/4/20252.35 SEK
12/3/20252.30 SEK
12/2/20252.20 SEK
12/1/20252.29 SEK
11/28/20252.13 SEK
11/27/20252.08 SEK
11/26/20251.94 SEK
11/25/20251.96 SEK
11/24/20252.00 SEK
11/21/20251.98 SEK
11/20/20252.06 SEK
11/19/20252.26 SEK
11/18/20252.29 SEK
11/17/20252.27 SEK
11/14/20252.32 SEK
11/13/20252.35 SEK
11/12/20252.38 SEK
11/11/20252.32 SEK
11/10/20252.38 SEK
11/7/20252.40 SEK
11/6/20252.35 SEK
11/5/20252.37 SEK
11/4/20252.41 SEK
11/3/20252.54 SEK
10/31/20252.49 SEK
10/30/20252.49 SEK
10/29/20252.41 SEK
10/28/20252.33 SEK
10/27/20252.44 SEK
10/24/20252.46 SEK
10/23/20252.46 SEK
10/22/20252.50 SEK
10/21/20252.50 SEK
10/20/20252.46 SEK
10/17/20252.52 SEK
10/16/20252.59 SEK
10/15/20252.68 SEK
10/14/20252.59 SEK
10/13/20252.60 SEK
10/10/20252.71 SEK
10/9/20252.72 SEK
10/8/20252.84 SEK
10/7/20252.81 SEK
10/6/20252.92 SEK
10/3/20252.85 SEK
10/2/20252.92 SEK
10/1/20252.91 SEK
9/30/20252.92 SEK
9/29/20252.92 SEK
9/26/20252.98 SEK
9/25/20253.03 SEK
9/24/20253.00 SEK
9/23/20253.00 SEK
9/22/20253.04 SEK
9/19/20253.07 SEK
9/18/20252.98 SEK
9/17/20252.99 SEK
9/16/20252.87 SEK
9/15/20252.92 SEK
9/12/20252.92 SEK
9/11/20252.93 SEK
9/10/20252.89 SEK
9/9/20252.72 SEK
9/8/20252.90 SEK
9/5/20252.69 SEK
9/4/20252.75 SEK
9/3/20252.76 SEK
9/2/20252.98 SEK
9/1/20253.00 SEK
8/29/20253.06 SEK
8/28/20253.13 SEK
8/27/20253.12 SEK
8/26/20253.09 SEK
8/25/20253.07 SEK
Access this data via the Eulerpool API
Get Free API Key

IRLAB Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
61.14 M SEK
-113.11 M SEK
-113.41 M SEK
Jan 1, 2023
5.68 M SEK
-180.77 M SEK
-177.84 M SEK
Jan 1, 2024
94.63 M SEK
-74.61 M SEK
-83.13 M SEK
Jan 1, 2025 (e)
113.71 M SEK
-37.74 M SEK
-123.27 M SEK
Jan 1, 2026 (e)
47.69 M SEK
-57.12 M SEK
-173.00 M SEK
Jan 1, 2027 (e)
417.76 M SEK
346.68 M SEK
0.00 SEK
Jan 1, 2028 (e)
661.84 M SEK
595.68 M SEK
0.00 SEK
Jan 1, 2029 (e)
901.46 M SEK
829.26 M SEK
0.00 SEK

IRLAB Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 24, 2026, 7:05 AM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e
––––––207.0061.005.0094.00113.0047.00417.00661.00901.00
–––––––-70.53-91.801,780.0020.21-58.41787.2358.5136.31
––––––60.87-104.92-2,440.00-43.62-43.62-43.62-43.62-43.62-43.62
-41.00-41.00-41.00-41.00-41.00-65.00126.00-64.00-122.00-41.00-49.29-20.50-181.88-288.31-392.99
-27.00-46.00-54.00-73.00-95.00-91.0052.00-113.00-180.00-74.00-37.00-57.00346.00595.00829.00
––––––25.12-185.25-3,600.00-78.72-32.74-121.2882.9790.0292.01
-11.00-42.00-56.00-74.00-96.00-91.0051.00-113.00-177.00-83.00-123.00-173.00–––
–281.8233.3332.1429.73-5.21-156.04-321.5756.64-53.1148.1940.65–––
10.0024.7634.3538.9241.3147.6851.7554.9454.9454.9454.9454.9454.9454.9454.94
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales IRLAB Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IRLAB Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IRLAB Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares IRLAB Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IRLAB Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

IRLAB Therapeutics stock margins

The IRLAB Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IRLAB Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IRLAB Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-44.03 %
- %
- %
Jan 1, 2021
60.66 %
25.30 %
24.92 %
Jan 1, 2022
-105.94 %
-185.01 %
-185.50 %
Jan 1, 2023
-2,161.57 %
-3,183.60 %
-3,132.07 %
Jan 1, 2024
-44.03 %
-78.84 %
-87.85 %
Jan 1, 2025 (e)
-44.03 %
-33.19 %
-108.41 %
Jan 1, 2026 (e)
-44.03 %
-119.79 %
-362.80 %
Jan 1, 2027 (e)
-44.03 %
82.99 %
0.00 %

IRLAB Therapeutics Stock Revenue, EBIT, Earnings per Share

The IRLAB Therapeutics earnings per share therefore indicates how much revenue IRLAB Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 SEK
-1.92 SEK
-1.92 SEK
Jan 1, 2021
4.02 SEK
1.02 SEK
1.00 SEK
Jan 1, 2022
1.11 SEK
-2.06 SEK
-2.06 SEK
Jan 1, 2023
0.10 SEK
-3.29 SEK
-3.24 SEK
Jan 1, 2024
1.72 SEK
-1.36 SEK
-1.51 SEK
Jan 1, 2025 (e)
2.07 SEK
-0.69 SEK
-2.24 SEK
Jan 1, 2026 (e)
0.87 SEK
-1.04 SEK
-3.15 SEK
Jan 1, 2027 (e)
7.60 SEK
6.31 SEK
0.00 SEK

IRLAB Therapeutics business model & stock analysis

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry.

IRLAB Therapeutics SWOT Analysis

Strengths

IRLAB Therapeutics AB has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company focuses on developing innovative therapies for neurological disorders, which enables it to tap into a growing market with limited treatment options. Secondly, IRLAB has a strong research and development team with expertise in neuroscience, allowing it to conduct thorough pre-clinical and clinical studies. This expertise grants the company a competitive advantage in the industry. Furthermore, IRLAB owns a robust intellectual property portfolio, which provides protection for its novel drug candidates and reduces the risk of competitors replicating its success.

Weaknesses

Despite its strengths, IRLAB Therapeutics AB faces several weaknesses that need to be addressed. The company's current drug pipeline is relatively limited, with only a few candidates in various stages of development. This lack of diversity in its portfolio could limit its ability to generate revenue and face challenges if any of the drug candidates fail in clinical trials. Additionally, IRLAB relies heavily on external partnerships and collaborations for research and development, which can lead to potential delays or dependencies on third-party organizations.

Opportunities

The pharmaceutical industry presents several opportunities for IRLAB Therapeutics AB. Firstly, the market for neurological disorder treatments is expected to grow significantly in the coming years, driven by an aging population and the increasing prevalence of conditions such as Parkinson's disease. This presents an opportunity for IRLAB to expand its product portfolio and capture a larger market share. Moreover, the company can explore strategic collaborations with other pharmaceutical firms or academic institutions to leverage their expertise and accelerate the development of new therapies.

Threats

IRLAB Therapeutics AB operates in an industry with various threats that need to be carefully managed. One major threat is the stringent regulatory environment governing the approval and commercialization of new drugs. Compliance with regulatory requirements can significantly impact timelines and increase costs for drug development. Additionally, the pharmaceutical sector is highly competitive, with large and established players dominating the market. This intense competition poses a challenge for IRLAB to differentiate itself and gain market acceptance for its therapies. Furthermore, the company is susceptible to potential patent infringements and intellectual property disputes, which could harm its competitive position.

IRLAB Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

IRLAB Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

IRLAB Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

IRLAB Therapeutics shares outstanding

The number of shares of IRLAB Therapeutics was 54.94 M in 2025. This indicates how many shares IRLAB Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
47.68 M Stocks
Jan 1, 2021
51.75 M Stocks
Jan 1, 2022
54.94 M Stocks
Jan 1, 2023
54.94 M Stocks
Jan 1, 2024
54.94 M Stocks
Jan 1, 2025 (e)
54.94 M Stocks
Jan 1, 2026 (e)
54.94 M Stocks
Jan 1, 2027 (e)
54.94 M Stocks

IRLAB Therapeutics stock splits

In IRLAB Therapeutics's history, there have been no stock splits.
Price targets and forecasts for IRLAB Therapeutics are not yet available.

IRLAB Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/22/2023-1.21SEK-11.16 MSEK-2022 Q4
11/9/2022-1.11SEK-11.16 MSEK-2022 Q3
8/24/2022-0.92SEK-11.16 MSEK-2022 Q2
5/11/2022-0.66SEK-11.16 MSEK-2022 Q1

IRLAB Therapeutics shareholder structure

% Name
0.56191%
Handelsbanken Kapitalförvaltning AB
Handelsbanken Kapitalförvaltning AB
0.45566%
SEB Investment Management AB
SEB Investment Management AB
0.08737%
Storebrand Kapitalforvaltning AS
Storebrand Kapitalforvaltning AS
0.05154%
Skandia Investment Management AB
Skandia Investment Management AB
0.02549%
Skandia Fonder AB
Skandia Fonder AB
0.02184%
Storebrand Fonder AB
Storebrand Fonder AB

IRLAB Therapeutics Executives and Management Board

15 members · avg. age 60 · 47 % women

NW

Dr. Nicholas Waters (60)

Executive Vice President, Head - Research and Development

3.45 M SEK

Management

JT

Dr. Joakim Tedroff (61)

Chief Medical Officer · since 2016

5,000.00 SEK
KT

Ms. Kristina Torfgard

Chief Executive Officer

–
RJ

Mr. Roy Jonebrant

Interim Chief Financial Officer

–
PS

Dr. Peder Svensson (60)

Director - Computational Chemistry and Biology, Chief Information Officer

–
CS

Dr. Clas Sonesson (61)

Chief Scientific Officer · since 2016

–
MJ

Ms. Maria Jalmelid (43)

Chief - Clinical Operations

–

Board of Directors

GO

Mr. Gunnar Olsson (70)

Director · since 2017

450,000.00 SEK
RP

Mr. Rein Piir (64)

Independent Director

275,000.00 SEK
LA

Mr. Lars Adlersson (58)

Independent Director

250,000.00 SEK
CL

Ms. Carola Lemne (67)

Independent Chairman of the Board

230,000.00 SEK
LT

Ms. Lena Torlegard (59)

Independent Director

230,000.00 SEK
SW

Dr. Susanna Holm Waters (56)

Director - Biology and Biostatistics

–

Frequently asked questions about IRLAB Therapeutics

IRLAB Therapeutics AB is a pharmaceutical company with a focus on developing novel treatments for Parkinson's disease and other central nervous system disorders. Their business model centers around research, development, and commercialization of drug candidates that target specific parts of the brain. By leveraging their expertise in drug discovery, IRLAB aims to improve the lives of patients by providing innovative solutions. With a strong commitment to scientific advancement and collaboration, IRLAB Therapeutics AB aims to establish itself as a leading player in the field of neurodegenerative diseases.

IRLAB Therapeutics AB is primarily active in the pharmaceutical industry.

The main competitors of IRLAB Therapeutics AB in the market are pharmaceutical companies that focus on developing therapeutics for neurological disorders and Parkinson's disease. Some notable competitors include Biogen Inc., Acorda Therapeutics Inc., and Adamas Pharmaceuticals Inc. These companies also strive to provide innovative treatment options for patients suffering from similar conditions. IRLAB Therapeutics AB differentiates itself by its unique investigational drug, IRL790, which has shown promising results in clinical trials for Parkinson's disease treatment.

IRLAB Therapeutics AB is a pharmaceutical company based in Sweden. It was founded in 2012 with a focus on developing innovative treatments for neurodegenerative diseases and Parkinson's disease. IRLAB Therapeutics AB is dedicated to improving the quality of life for patients affected by these conditions. The company's research and development efforts are centered around exploring new drug candidates and therapeutic solutions. IRLAB Therapeutics AB aims to address the unmet medical needs in neurology and create effective medications that can significantly impact patients' lives. With a strong commitment to scientific excellence, IRLAB Therapeutics AB is actively pursuing advancements in the field of neurodegenerative diseases.

IRLAB Therapeutics AB has achieved several significant milestones in its corporate journey. In recent years, the company has made remarkable progress in the field of neurological disorders. IRLAB successfully completed a Phase 2b study for its candidate, IRL752, intended for the treatment of Parkinson's disease psychosis. The positive results demonstrated the drug's potential in addressing this challenging condition. Additionally, IRLAB advanced its Phase 2a study for IRL790, a drug candidate targeting Parkinson's disease symptoms, such as abnormal involuntary movements. The company's commitment to innovative therapies and dedication to improving patients' lives showcases IRLAB Therapeutics AB as a leading player in the neurology sector.

IRLAB Therapeutics AB is primarily present in Sweden, where it is headquartered.

IRLAB Therapeutics AB is dedicated to improving the lives of patients suffering from neurological disorders. The company focuses on developing innovative pharmaceuticals that target unmet medical needs, particularly within the field of Parkinson's disease. IRLAB Therapeutics AB's core values include a commitment to scientific excellence, collaboration, and a patient-centered approach. By combining cutting-edge research with a deep understanding of the complexities of neurological disorders, IRLAB Therapeutics AB strives to bring transformative treatments to market and make a positive impact on the lives of those affected by these conditions.

Converted at the current exchange rate, the IRLAB Therapeutics share trades at 0.16 EUR (1.72 SEK).

The IRLAB Therapeutics share (IRLAB A.ST) is listed on 3 stock exchanges, including: Frankfurt (6IRA.F).

IRLAB Therapeutics AB is a biopharmaceutical company based in Sweden that specializes in the discovery and development of innovative drugs for neurodegenerative diseases and pain. Its business model is based on the identification of new compounds, preclinical evaluation, and conducting clinical studies to demonstrate their effectiveness and safety. IRLAB's vision is to help patients achieve a better quality of life by developing drugs that are effective in treating diseases such as Parkinson's, Huntington's, Alzheimer's, and pain. The company's research and development activities are divided into different business areas, including academic research and pharmaceutical development. IRLAB's academic research involves collaborating with renowned academic institutions, universities, and private laboratories worldwide. The company is also involved in researching new technologies and methods to develop better drugs and accelerate the process. On the pharmaceutical development level, IRLAB focuses on two main categories of compounds. On one hand, they are developing selective dopamine concentration modifiers (SDMs) that can improve the function of dopamine neurons in Parkinson's patients. On the other hand, they are developing selective catechol-O-methyltransferase inhibitors (COMT inhibitors) that can be used in the treatment of Parkinson's. The company has also developed a pipeline of drugs for Huntington's disease and pain, which are in various stages of clinical development. IRLAB works closely with medical experts and patient groups to ensure that their drugs meet patient needs. Additionally, the company has entered into a licensing agreement for the commercialization of an already approved product for psychiatric disorders. This product, called IRLAB technology, is for the long-term treatment of panic disorders and generalized anxiety disorders. IRLAB's business model also includes strong partnerships with other pharmaceutical companies and institutional investors to mobilize capital for research and development. The company has entered into several partnerships with other companies to advance the development and commercialization of its products. Overall, IRLAB Therapeutics AB's business model is based on developing innovative drugs for serious neurodegenerative diseases and pain. Through collaboration with leading academics and partners, the company has built a strong pipeline of drugs aiming to help patients achieve a better quality of life. IRLAB is committed to continuous exploration of new technologies and methods to improve the drug development process and better meet the needs of patients.

The expected revenue of IRLAB Therapeutics is 47.69 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IRLAB Therapeutics is -173.00 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IRLAB Therapeutics is currently -0.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IRLAB Therapeutics stock.

The price-to-sales ratio (P/S) of IRLAB Therapeutics is currently 1.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IRLAB Therapeutics stock.

The Eulerpool Quality Score for IRLAB Therapeutics is 1/10.

The ISIN of IRLAB Therapeutics is SE0012675361. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of IRLAB Therapeutics is A2PLBE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of IRLAB Therapeutics is IRLAB A.ST. The ticker symbol is used to trade IRLAB Therapeutics shares on the stock exchange.

IRLAB Therapeutics paid dividends every year for the past 0 years.

IRLAB Therapeutics is assigned to the 'Health' sector.

The dividends of IRLAB Therapeutics are distributed in SEK.

All fundamentals and in-depth analysis of IRLAB Therapeutics

Our stock analysis for IRLAB Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRLAB Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

IRLAB Therapeutics Stock
IRLAB Therapeutics Revenue→
IRLAB Therapeutics Stock
IRLAB Therapeutics Net Income→
IRLAB Therapeutics Stock
IRLAB Therapeutics P/E→
IRLAB Therapeutics Stock
IRLAB Therapeutics P/S→
IRLAB Therapeutics Stock
IRLAB Therapeutics EBIT→
IRLAB Therapeutics Stock
IRLAB Therapeutics Dividend→
IRLAB Therapeutics Stock
IRLAB Therapeutics Directors Dealings→
IRLAB Therapeutics Stock
IRLAB Therapeutics Stocks→
IRLAB Therapeutics Stock
IRLAB Therapeutics Market capitalization→
IRLAB Therapeutics Stock
IRLAB Therapeutics Debt→
IRLAB Therapeutics Stock
IRLAB Therapeutics Liabilities→
IRLAB Therapeutics Stock
IRLAB Therapeutics Equity→
IRLAB Therapeutics Stock
IRLAB Therapeutics AAQS→
IRLAB Therapeutics Stock
IRLAB Therapeutics Employees→
IRLAB Therapeutics Stock
IRLAB Therapeutics ROE→
IRLAB Therapeutics Stock
IRLAB Therapeutics ROA→
IRLAB Therapeutics Stock
IRLAB Therapeutics ROCE→
IRLAB Therapeutics Stock
IRLAB Therapeutics News→
IRLAB Therapeutics Stock
IRLAB Therapeutics Analyst Price Targets→

Health Stocks

Ironwood PharmaceuticalsIRIDEXISEC HealthcareiRhythm Holdings,Ishita Drugs and IndustriesiRay GroupIsland PharmaceuticalsIRadimedIsofol Medical AB (publ)IQVIA HoldingsiSpecimenIpsenAll Stocks A–Z →